Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates. “This sales ...

Gardasil, which prevents cancers caused by the human papillomavirus, has been one of Merck's top growth drivers aside from Keytruda, and much of its international growth had come from China before ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $118.00. Leverage the power ...

By Michael Erman and Mariam Sunny (Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.